摘要
目的:评价2HRZE/4HR和2HL2LfxE/4HL2两种方案治疗初治肺结核合并慢性乙型肝炎病毒携带者的疗效和安全性。方法:选取笔者所在医院2014年3月-2017年3月符合入选标准的初治肺结核合并慢性乙型肝炎病毒携带者160例作为研究对象,随机分试验组80例和对照组80例。最终资料完整的有153例,其中试验组78例,对照组75例,两组年龄、性别、病情严重程度相当,具有可比性(P>0.05)。对照组给予2HRZE/4HR的抗结核治疗方案,试验组给予2HL2LfxE/4HL2治疗方案。比较两组患者治疗后临床症状缓解时间、胸部CT病灶吸收情况、痰检转阴或转阳以及肝功能损害程度。结果:与对照组比较,试验组在症状缓解时间、胸部CT病灶吸收情况和痰菌阴转或阳转情况均无统计学差异(P>0.05);两组1年后胸部CT显示病灶均无复发且痰菌均为阴性。与对照组比较,试验组肝功能损伤较轻,两组比较差异有统计学意义(P<0.05)。结论:对于初治肺结核合并慢性乙型肝炎病毒携带,两种方案疗效相当,但2HL2LfxE/4HL2方案肝损害较轻,可作为临床首选方案。
Objective:To evaluate the efficacy and safety of two schemes,2 HRZE/4 HR and 2 HL2 LfxE/4 HL2,in the treatment of primary treated pulmonary tuberculosis accompanied with chronic hepatitis B virus carriers.Method:160 patients,primary treated pulmonary tuberculosis accompanied with chronic hepatitis B virus carriers who meet the inclusion criteria in our hospital from March 2014 to March 2017,were selected as the research objects,and were randomly divided into 80 patients in the experimental group and 80 patients in the control group.There were 153 patients with complete data,including 78 cases in the experimental group and 75 cases in the control group.The age,gender and severity of the disease in the two groups were comparable(P>0.05).The patients in control group were given 2 HRZE/4 HR anti-tuberculosis treatment scheme,while that in the experimental group were given 2 HL2 LfxE/4 HL2 treatment scheme.The clinical symptom relief time,chest CT lesion absorption,sputum negative or positive transformation and liver function damage were compared between the two groups.Result:Compared with the control group,there were no statistically significant differences in symptom relief time,chest CT lesion absorption and sputum negative or positive transfer in the experimental group(P>0.05).Chest CT showed no recurrence and negative sputum in both groups after 1 year.Compared with the control group,the liver function injury in the experimental group was relatively mild,and the difference between the two groups was statistically significant(P<0.05).Conclusion:The two schemes have equal efficacy for the primary treated pulmonary tuberculosis accompanied with chronic hepatitis B virus carriers,but the 2 HL2 LfxE/4 HL2 scheme has relatively mild liver damage,which can be used as first choice in the clinical practice.
作者
陈展峰
蔡茂胜
傅阿芬
CHENZhanfeng;CAI Maosheng;FU Afen(Shishi General Hospital,Shishi 362700,China)
出处
《中外医学研究》
2019年第21期42-45,共4页
CHINESE AND FOREIGN MEDICAL RESEARCH
基金
石狮市科技局重点项目(项目编号:2015SK08)
关键词
初治肺结核
慢性乙型肝炎病毒
抗结核药
疗效
安全性
Primary treated tuberculosis
Chronic hepatitis B
Anti-tubercular agents
Efficacy
Safety
